ABP-PUBLISHING
20.4.2021 11:02:09 CEST | Business Wire | Press release
The annual reports inform that the production and, thus, sales grew significantly whereas the audience preferences veered round into health and relations fields.
Besides, in 2021, the publishing house plans to acquire new genres in non-fiction and cooperate with new promising authors, retailers, and markets.
Although the circumstances made the editorial team work remotely, the number of published audiobooks did not diminish but increased. In particular, 109 books were recorded in 2020. The company published, among others, such bestsellers as Educated by Tara Westover, Flow by Mihaly Csikszentmihalyi, and Talking to Strangers by Malcolm Gladwell (German); Money. Master The Game by Tony Robbins, Bad Blood by John Carreyrou, and Big Magic by Elizabeth Gilbert (French); Atomic Habits by James Clear, Outliers by Malcolm Gladwell, and Becoming Supernatural by Joe Dispenza (Italian).
Additionally, in 2020, the publishing house started acquiring new languages producing books in Swedish, Turkish, Spanish, Norwegian, and Japanese.
The increase in production led to the rise in sales, logically. The sales report for 2020 showed a growth of 60 per cent, comparing to 2019. As mentioned, the listeners downloaded more books about health and relations, which is evidence of a slight change in audience preferences.
Further, in 2020, ABP Publishing worked on its ABP Verlag, ABP Editions, and ABP Editore brands. Every subsidiary got a new logotype and site. Moreover, each of the ABP Publishing books can be associated with the publisher, thanks to the standardised cover design.
Following the listeners' interests, in 2021, ABP Publishing plans to release audiobooks in fields and topics the company did not work with before, for instance, publicism and fiction. As an example, the German division has already published Demi Moore's autobiography while the French department is preparing the timeless classic bestseller Atlas Shrugged by Ayn Rand. Besides, the publisher increases the number of titles in relationship and parenting and popular science genres. It is important that despite the growing number of titles, the company keeps the high quality of audiobooks, practising an attentive approach to the voice-overs cast and music and dramatic audiobooks style.
Nevertheless, in the coming years, most publishers in the digital field will face the expansion of subscription and streaming model of distribution. The listeners appreciated the profit of the unlimited access to audiobooks, whereas the publishing houses are switching to a new reality reluctantly. Anyway, all the publishing companies will have to find a balance between listeners' wishes and desirable income. ABP Publishing believes that the changes will be advantageous for all the market participants and cause the better quality of published audiobooks in competitive terms.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210420005017/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HTEC Research: Only One in Three Healthcare Organizations is Ready to Scale AI28.4.2026 15:22:00 CEST | Press release
Healthcare and life sciences leaders are advancing AI with caution—fragmentation, capability gaps, and execution challenges are slowing enterprise-wide impact AI is already embedded across healthcare and life sciences. Most organizations are deploying it, and confidence in its potential is high. Yet for many, the real challenge is only just beginning. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428872907/en/ HTEC, a global AI‑first provider of software and hardware design and engineering services, today released new research based on a global survey of 253 C-level HLS executives across the United States, United Kingdom, Germany, Spain, Saudi Arabia, and the UAE. AI is already embedded across healthcare and life sciences. Most organizations are deploying AI, and confidence in its potential is high. Yet for many, the real challenge is only just beginning. HTEC, a global AI‑first provider of software and hardware design a
JPMorganChase Named First-Ever Global Banking Partner of the Olympic Games28.4.2026 15:00:00 CEST | Press release
International Olympic Committee and JPMorganChase Announce Landmark Global Olympic Partnership The International Olympic Committee (IOC) and JPMorganChase today announced a landmark Worldwide Olympic Partnership, making JPMorganChase the first Global Banking Partner in Olympic history. The partnership includes the Los Angeles 2028 Olympic and Paralympic Games (LA28 Games) and the French Alps 2030 Olympic and Paralympic Winter Games. The firm has also reached an agreement with LA28 to become the Official Bank of Team USA and LA28, and a Founding Partner of the LA28 Games. The partnership reflects a shared commitment to ambition and excellence, and places athletes and communities at its core. Kirsty Coventry, President of the IOC, commented: “JPMorganChase is the first Global Partner from the banking sector in Olympic history, and we are proud to welcome them to the Worldwide Olympic Partner programme. This partnership reflects our shared values of ambition, excellence and will support t
BlueSnap, Powered by Payroc, Launches Local Acquiring in New Zealand to Boost Approval Rates and Reduce Cross-Border Costs28.4.2026 15:00:00 CEST | Press release
BlueSnap, powered by Payroc, today announced the availability of local acquiring in New Zealand, expanding its global payment orchestration capabilities and enabling businesses to process transactions domestically. Local acquiring allows businesses with a legal entity in New Zealand to process payments through domestic acquiring banks rather than routing transactions cross-border. This helps increase authorization rates, reduce payment failures, and lower transaction costs, critical factors for businesses selling into the region. Why Local Acquiring in New Zealand Matters For B2B and B2C businesses operating globally, cross-border payments often lead to higher fees and lower approval rates. Building local acquiring infrastructure independently requires managing multiple bank relationships, compliance, and integrations, making it costly and complex. BlueSnap simplifies this by providing local acquiring through a single platform, allowing businesses with a legal entity in New Zealand to
Vensica Medical Receives FDA IND Clearance to Initiate Phase 2 Study of ViXe, Its Needle-Free Xeomin® Delivery System for Overactive Bladder28.4.2026 14:42:00 CEST | Press release
Vensica Medical, a clinical-stage company developing needle-free therapeutic delivery solutions for urologic diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application to initiate a Phase 2 clinical trial of ViXe. The study will evaluate the Vibe® ultrasound-based, needle-free drug delivery system in combination with Xeomin® (incobotulinumtoxinA) for the treatment of overactive bladder (OAB). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414145279/en/ Avner Geva, Cofounder, CEO (left), and Avi Eftel, Cofounder, CTO (right) Overactive bladder affects an estimated 33 million adults in the United States and is characterized by urinary urgency, frequency, and incontinence. While intravesical botulinum toxin injection is an established second-line treatment, the invasive procedure limits patient access and acceptance. The ViXe program is desi
Printing the Future of Oncology: CTIBIOTECH Invests €3M and Secures €1.25M from France 2030 to Revolutionize Personalized Cancer Care28.4.2026 14:28:00 CEST | Press release
CTIBIOTECH™, a leading innovator in advanced human tissue engineering, proudly announces CTIONCOTEST™ platform is awarded Major Bpifrance Funding to Industrialize 3D Bioprinted Cancer Models CTIBIOTECH Announces the CTIONCOTEST ™ Project to Revolutionize Cancer Research with 3D Bioprinted Microtumors, Backed by France 2030 and Bpifrance This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428242352/en/ The CTIONCOTEST™ platform by CTIBIOTECH is an innovative 3D bioprinting technology that revolutionizes preclinical cancer research . It provides an automated, industrial-scale process to produce high-throughput, patient-specific human "microtumors" directly from primary tumor cells . Designed to tackle the 95% clinical failure rate of new cancer drugs, it faithfully replicates the complex tumor microenvironment, including critical hypoxic and necrotic zones . Targeting high-mortality breast, colon, and pancreatic cancers, the pla
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
